Table 2. Changes in Data From Baseline to 3 Months After Initial Treatment.
| Parameter | Baseline | 3 months | P |
|---|---|---|---|
| d-ROMs, Carr U | < 0.01** | ||
| OC group (N = 17) | 321 ± 61 | 512 ± 79 | |
| DG group (N = 10) | 356 ± 70 | 339 ± 31 | |
| BAP, µM | 0.21 | ||
| OC group (N = 17) | 2,033 ± 179 | 2,029 ± 161 | |
| DG group (N = 10) | 1,953 ± 191 | 1,970 ± 117 | |
| High-sensitivity CRP, mg/dL | 0.01* | ||
| OC group (N = 17) | 0.02 (0.01 - 0.05) | 0.10 (0.03 - 0.22) | |
| DG group (N = 10) | 0.01 (0.01 - 0.02) | 0.01 (0.01 - 0.02) | |
| WBC, /µL | 0.28 | ||
| OC group (N = 17) | 5,688 ± 1,319 | 5,994 ± 1,134 | |
| DG group (N = 10) | 5,140 ± 1,088 | 5,550 ± 1,527 | |
| Platelet, × 104/µL | 0.40 | ||
| OC group (N = 17) | 26.1 ± 5.0 | 28.4 ± 7.1 | |
| DG group (N = 10) | 29.0 ± 6.6 | 29.4 ± 5.5 | |
| Fibrinogen, mg/dL | 0.06 | ||
| OC group (N = 17) | 275 ± 78 | 278 ± 68 | |
| DG group (N = 10) | 237 ± 27 | 234 ± 28 | |
| LDL-cholesterol, mg/dL | 0.75 | ||
| OC group (N = 17) | 100 ± 31 | 108 ± 31 | |
| DG group (N = 10) | 98 ± 26 | 103 ± 24 |
OC: oral contraceptive; DG: dydrogesterone; WBC: white blood coun; LDL: low-density lipoprotein; HDL: high-density lipoprotein; ROMs: reactive oxygen metabolites; BAP: biological antioxidant potential. Data are presented as means ± standard deviations or medians (interquartile ranges). *P < 0.05, **P < 0.01: comparison between the OC and DG groups by two-way repeated measure ANOVA.